{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T06:40:00Z","timestamp":1792564800381,"version":"4.5.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Shanghai Pujiang Talents Program","award":["No. 23PJD011"],"award-info":[{"award-number":["No. 23PJD011"]}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2021YFA1301402"],"award-info":[{"award-number":["2021YFA1301402"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC3402700"],"award-info":[{"award-number":["2023YFC3402700"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"DOI":"10.1245\/s10434-026-20600-9","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:27:29Z","timestamp":1790612849000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A Novel Prognostic Stratification for Patients with Non-small Cell Lung Cancer Following Surgical Resection After Neoadjuvant Therapy: A Retrospective Cohort Study"],"prefix":"10.1245","author":[{"given":"Yongqiang","family":"Ao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyu","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiazhe","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caiying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haikun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahao","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianyong","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"issue":"17","key":"20600_CR1","doi-asserted-by":"publisher","first-page":"3249","DOI":"10.1200\/JCO.22.02509","volume":"41","author":"O Akinboro","year":"2023","unstructured":"Akinboro O, Drezner N, Amatya A, et al. US Food and Drug Administration Approval Summary: nivolumab plus platinum-doublet chemotherapy for the neoadjuvant treatment of patients with resectable non-small-cell lung cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2023;41(17):3249\u201359.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol."},{"issue":"8","key":"20600_CR2","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1056\/NEJMoa2502931","volume":"393","author":"PM Forde","year":"2025","unstructured":"Forde PM, Spicer JD, Provencio M, et al. Overall survival with neoadjuvant nivolumab plus chemotherapy in lung cancer. N Engl J Med. 2025;393(8):741\u201352.","journal-title":"N Engl J Med."},{"issue":"6","key":"20600_CR3","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1056\/NEJMoa2215530","volume":"389","author":"M Provencio","year":"2023","unstructured":"Provencio M, Nadal E, Gonz\u00e1lez-Larriba JL, et al. Perioperative nivolumab and chemotherapy in stage III non-small-cell lung cancer. N Engl J Med. 2023;389(6):504\u201313.","journal-title":"N Engl J Med."},{"issue":"21","key":"20600_CR4","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","volume":"386","author":"PM Forde","year":"2022","unstructured":"Forde PM, Spicer J, Lu S, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med. 2022;386(21):1973\u201385.","journal-title":"N Engl J Med."},{"issue":"1","key":"20600_CR5","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/s41591-023-02660-6","volume":"30","author":"JS Deutsch","year":"2024","unstructured":"Deutsch JS, Cimino-Mathews A, Thompson E, et al. Association between pathologic response and survival after neoadjuvant therapy in lung cancer. Nat Med. 2024;30(1):218\u201328.","journal-title":"Nat Med."},{"issue":"5","key":"20600_CR6","first-page":"709","volume":"15","author":"WD Travis","year":"2020","unstructured":"Travis WD, Dacic S, Wistuba I, et al. IASLC Multidisciplinary recommendations for pathologic assessment of lung cancer resection specimens after neoadjuvant therapy. J Thorac Oncol Off Pub Int Assoc Study Lung Cancer. 2020;15(5):709\u201340.","journal-title":"J Thorac Oncol Off Pub Int Assoc Study Lung Cancer."},{"issue":"19","key":"20600_CR7","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1056\/NEJMoa2311926","volume":"390","author":"T Cascone","year":"2024","unstructured":"Cascone T, Awad MM, Spicer JD, et al. Perioperative nivolumab in resectable lung cancer. N Engl J Med. 2024;390(19):1756\u201369.","journal-title":"N Engl J Med."},{"issue":"31","key":"20600_CR8","first-page":"e13256","volume":"12","author":"B Luo","year":"2025","unstructured":"Luo B, Luo Y, Chen S, et al. Real-time evolutionary landscape of the bronchial epithelium and corresponding dynamic immune cell alterations in lung squamous cell carcinogenesis. Adv Sci (Weinheim BadenWurttemberg Germany). 2025;12(31):e13256.","journal-title":"Adv Sci (Weinheim BadenWurttemberg Germany)."},{"issue":"11","key":"20600_CR9","doi-asserted-by":"publisher","first-page":"3081","DOI":"10.1016\/j.cell.2025.03.018","volume":"188","author":"Z Liu","year":"2025","unstructured":"Liu Z, Yang Z, Wu J, et al. A single-cell atlas reveals immune heterogeneity in anti-PD-1-treated non-small cell lung cancer. Cell. 2025;188(11):3081-3096.e3019.","journal-title":"Cell."},{"issue":"6","key":"20600_CR10","doi-asserted-by":"publisher","first-page":"e3694","DOI":"10.1002\/jgm.3694","volume":"26","author":"X Fang","year":"2024","unstructured":"Fang X, Li D, Wan S, et al. Insights into the heterogeneity of the tumor microenvironment in lung adenocarcinoma and squamous carcinoma through single-cell transcriptomic analysis: implications for distinct immunotherapy outcomes. J Gene Med. 2024;26(6):e3694.","journal-title":"J Gene Med."},{"issue":"7948","key":"20600_CR11","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/s41586-022-05672-3","volume":"614","author":"M Sorin","year":"2023","unstructured":"Sorin M, Rezanejad M, Karimi E, et al. Single-cell spatial landscapes of the lung tumour immune microenvironment. Nature. 2023;614(7948):548\u201354.","journal-title":"Nature."},{"issue":"3","key":"20600_CR12","first-page":"482","volume":"14","author":"Y Qu","year":"2019","unstructured":"Qu Y, Emoto K, Eguchi T, et al. Pathologic assessment after neoadjuvant chemotherapy for NSCLC: importance and implications of distinguishing adenocarcinoma from squamous cell carcinoma. J Thorac Oncol Off Pub Int Assoc Study Lung Cancer. 2019;14(3):482\u201393.","journal-title":"J Thorac Oncol Off Pub Int Assoc Study Lung Cancer."},{"issue":"11","key":"20600_CR13","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1038\/s41379-021-00871-1","volume":"34","author":"X Liu","year":"2021","unstructured":"Liu X, Sun W, Wu J, et al. Major pathologic response assessment and clinical significance of metastatic lymph nodes after neoadjuvant therapy for non-small cell lung cancer. Mod Pathol. 2021;34(11):1990\u20138.","journal-title":"Mod Pathol."},{"issue":"1","key":"20600_CR14","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1093\/ejcts\/ezaa290","volume":"59","author":"EM Corsini","year":"2021","unstructured":"Corsini EM, Weissferdt A, Pataer A, et al. Pathological nodal disease defines survival outcomes in patients with lung cancer with tumour major pathological response following neoadjuvant chemotherapy. Eur J Cardiothorac Surg Off J Eur Assoc Cardiothorac Surg. 2021;59(1):100\u20138.","journal-title":"Eur J Cardiothorac Surg Off J Eur Assoc Cardiothorac Surg."},{"issue":"1","key":"20600_CR15","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s40164-023-00401-6","volume":"12","author":"H Deng","year":"2023","unstructured":"Deng H, Xiong S, Zhong R, et al. Major pathologic response\" in lymph nodes: a modified nodal classification for non-small cell lung cancer patients treated with neoadjuvant immunochemotherapy. Exp Hematol Oncol. 2023;12(1):40.","journal-title":"Exp Hematol Oncol."},{"issue":"5","key":"20600_CR16","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.cllc.2025.04.004","volume":"26","author":"R Ma","year":"2025","unstructured":"Ma R, Yang H, Ge Y, et al. Prognostic implications of lymph node status in non-small-cell lung cancer patients before and after neoadjuvant chemoimmunotherapy: a multicenter retrospective study. Clin Lung Cancer. 2025;26(5):370\u201383.","journal-title":"Clin Lung Cancer."},{"issue":"7","key":"20600_CR17","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1001\/jamaoncol.2025.1115","volume":"11","author":"B Ricciuti","year":"2025","unstructured":"Ricciuti B, Fusco F, Cooper A, et al. Neoadjuvant PD-1 and PD-L1 blockade with chemotherapy for borderline resectable and unresectable stage III non-small cell lung cancer. JAMA Oncol. 2025;11(7):735\u201341.","journal-title":"JAMA Oncol."},{"issue":"1","key":"20600_CR18","doi-asserted-by":"publisher","first-page":"2453825","DOI":"10.1080\/07853890.2025.2453825","volume":"57","author":"Y Xu","year":"2025","unstructured":"Xu Y, Ma D, Qin Y, Liu H. Prognostic significance of pathological response and lymph node status in neoadjuvant immunotherapy for potentially resectable non-small cell lung cancer. Ann Med. 2025;57(1):2453825.","journal-title":"Ann Med."},{"key":"20600_CR19","doi-asserted-by":"publisher","DOI":"10.70389\/PJS.100081","author":"AA Riaz","year":"2025","unstructured":"Riaz AA, Ginimol M, Rasha R, et al. Revised strengthening the reporting of cohort, cross-sectional and case-control studies in surgery an update for the age of artificial intelligence. Premier J Sci. 2025. https:\/\/doi.org\/10.70389\/PJS.100081.","journal-title":"Premier J Sci."},{"issue":"1","key":"20600_CR20","first-page":"82","volume":"4","author":"H Zhai","year":"2015","unstructured":"Zhai H, Zhong W, Yang X, Wu YL. Neoadjuvant and adjuvant epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy for lung cancer. Transl Lung Cancer Res. 2015;4(1):82\u201393.","journal-title":"Transl Lung Cancer Res."},{"issue":"5","key":"20600_CR21","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/S2213-2600(23)00431-9","volume":"12","author":"H Zhong","year":"2024","unstructured":"Zhong H, Sun S, Chen J, et al. First-line penpulimab combined with paclitaxel and carboplatin for metastatic squamous non-small-cell lung cancer in China (AK105-302): a multicentre, randomised, double-blind, placebo-controlled phase 3 clinical trial. Lancet Respir Med. 2024;12(5):355\u201365.","journal-title":"Lancet. Respir Med."},{"issue":"2","key":"20600_CR22","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.ccell.2023.12.004","volume":"42","author":"C Zhou","year":"2024","unstructured":"Zhou C, Hu Y, Arkania E, et al. A global phase 3 study of serplulimab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (ASTRUM-004). Cancer Cell. 2024;42(2):198-208.e193.","journal-title":"Cancer Cell."},{"issue":"5","key":"20600_CR23","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.cllc.2023.03.014","volume":"24","author":"N Meshulami","year":"2023","unstructured":"Meshulami N, Tavolacci S, de Miguel-Perez D, Rolfo C, Mack PC, Hirsch FR. Predictive capability of PD-L1 protein expression for patients with advanced NSCLC: any differences based on histology? Clin Lung Cancer. 2023;24(5):401\u20136.","journal-title":"Clin Lung Cancer."},{"issue":"1","key":"20600_CR24","first-page":"100763","volume":"6","author":"Y Dong","year":"2025","unstructured":"Dong Y, Xu L, Wen J, et al. Prognostic impact of adjuvant immunotherapy in patients with resectable NSCLC after neoadjuvant chemoimmunotherapy: a brief report. JTO Clin Res Rep. 2025;6(1):100763.","journal-title":"JTO Clin Res Rep."},{"key":"20600_CR25","doi-asserted-by":"publisher","first-page":"108634","DOI":"10.1016\/j.lungcan.2025.108634","volume":"206","author":"Y Shi","year":"2025","unstructured":"Shi Y, Chen R, Xiong Y, et al. MRD status combined with TNM staging optimizes postoperative prognostic stratification in non-small cell lung cancer: a meta-analysis and systematic review. Lung Cancer. 2025;206:108634.","journal-title":"Lung Cancer."},{"issue":"21","key":"20600_CR26","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1056\/NEJMoa1716078","volume":"378","author":"PM Forde","year":"2018","unstructured":"Forde PM, Chaft JE, Smith KN, et al. Neoadjuvant PD-1 blockade in resectable lung cancer. New Engl J Med. 2018;378(21):1976\u201386.","journal-title":"New Engl J Med."},{"issue":"4","key":"20600_CR27","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1158\/1078-0432.CCR-22-2994","volume":"29","author":"S Rosner","year":"2023","unstructured":"Rosner S, Reuss JE, Zahurak M, et al. Five-year clinical outcomes after neoadjuvant nivolumab in resectable non-small cell lung cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2023;29(4):705\u201310.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res."},{"issue":"8","key":"20600_CR28","first-page":"1289","volume":"16","author":"A Pataer","year":"2021","unstructured":"Pataer A, Weissferdt A, Vaporciyan AA, et al. Evaluation of pathologic response in lymph nodes of patients with lung cancer receiving neoadjuvant chemotherapy. J Thorac Oncol Off Pub Int Assoc Study Lung Cancer. 2021;16(8):1289\u201397.","journal-title":"J Thorac Oncol Off Pub Int Assoc Study Lung Cancer."},{"issue":"26","key":"20600_CR29","doi-asserted-by":"publisher","first-page":"3105","DOI":"10.1200\/JCO.24.00071","volume":"42","author":"CM Blakely","year":"2024","unstructured":"Blakely CM, Urisman A, Gubens MA, et al. Neoadjuvant osimertinib for the treatment of stage I-IIIA epidermal growth factor receptor-mutated non-small cell lung cancer: a phase II multicenter study. J Clin Oncol Off J Am Soc Clin Oncol. 2024;42(26):3105\u201314.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol."},{"issue":"7","key":"20600_CR30","doi-asserted-by":"publisher","first-page":"e2521197","DOI":"10.1001\/jamanetworkopen.2025.21197","volume":"8","author":"K Sugumar","year":"2025","unstructured":"Sugumar K, Lie JJ, Stucky CC, et al. Pathologic complete response and survival in rectal cancer: a systematic review and meta-analysis. JAMA Netw Open. 2025;8(7):e2521197.","journal-title":"JAMA Netw Open."},{"issue":"1","key":"20600_CR31","first-page":"34","volume":"20","author":"D Uprety","year":"2025","unstructured":"Uprety D, Roden AC, Peters S. Adjuvant immunotherapy should be used in patients with non-small cell carcinoma with a pathologic complete response to neoadjuvant immunotherapy. J Thorac Oncol Off Pub Int Assoc Study Lung Cancer. 2025;20(1):34\u20138.","journal-title":"J Thorac Oncol Off Pub Int Assoc Study Lung Cancer."},{"issue":"1","key":"20600_CR32","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1186\/s12890-025-03822-7","volume":"25","author":"M Fazl\u0131oglu","year":"2025","unstructured":"Fazl\u0131oglu M, Erdogu V, Citak N, Fazl\u0131oglu N, Metin M. Surgery after neoadjuvant therapy in patients with resectable stage IIIB\/N2 non-small cell lung cancer. BMC Pulm Med. 2025;25(1):344.","journal-title":"BMC Pulm Med."},{"issue":"1","key":"20600_CR33","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s00345-022-04187-w","volume":"41","author":"J Wagner","year":"2023","unstructured":"Wagner J, Simon R, B\u00fcchler JW, et al. Both radiographical and pathological lymph node statuses are independent predictors for survival following neoadjuvant chemotherapy and radical cystectomy for cT3\/4 or cN+ bladder cancer. World J Urol. 2023;41(1):101\u20137.","journal-title":"World J Urol."},{"key":"20600_CR34","doi-asserted-by":"publisher","first-page":"S149","DOI":"10.1016\/j.jtho.2025.09.276","volume":"20","author":"Q Liang","year":"2025","unstructured":"Liang Q. P1.07.33 Sublobar Resection versus lobectomy in peripheral NSCLC after neoadjuvant chemoimmunotherapy: a retrospective study. J Thorac Oncol. 2025;20:S149\u201350.","journal-title":"J Thorac Oncol."},{"issue":"2","key":"20600_CR35","doi-asserted-by":"publisher","first-page":"e54","DOI":"10.1016\/j.jtcvs.2024.12.026","volume":"170","author":"H Deng","year":"2025","unstructured":"Deng H, Yu Z, Pan Y, et al. SEGMENTECTOMY\/WEDGE resection following neoadjuvant\/induction immunochemotherapy in non-small cell lung cancer: is it justified? J Thorac Cardiovasc Surg. 2025;170(2):e54\u20138.","journal-title":"J Thorac Cardiovasc Surg."},{"issue":"12","key":"20600_CR36","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1200\/JCO.21.02019","volume":"40","author":"JMN Lopes Cardozo","year":"2022","unstructured":"Lopes Cardozo JMN, Drukker CA, Rutgers EJT, et al. Outcome of patients with an ultralow-risk 70-gene signature in the MINDACT trial. J Clin Oncol Off J Am Soc Clin Oncol. 2022;40(12):1335\u201345.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol."},{"issue":"5","key":"20600_CR37","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1001\/jamaoncol.2024.0057","volume":"10","author":"M Sorin","year":"2024","unstructured":"Sorin M, Prosty C, Ghaleb L, et al. Neoadjuvant chemoimmunotherapy for NSCLC: a systematic review and meta-analysis. JAMA Oncol. 2024;10(5):621\u201333.","journal-title":"JAMA Oncol."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-20600-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-20600-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-20600-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:03:12Z","timestamp":1790658192000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-026-20600-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":37,"alternative-id":["20600"],"URL":"https:\/\/doi.org\/10.1245\/s10434-026-20600-9","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,28]]},"assertion":[{"value":"25 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors declare that they have no competing interests.","order":1,"name":"Ethics","label":"Disclosures","group":{"name":"EthicsHeading","label":"Ethics"}}]}}